Doctor speaking with patient. Image credit: Canva
Gastrointestinal (GI) cancer affects the organs of the digestive tract, such as the stomach, large and small intestine, pancreas, colon, liver and biliary system. Certain gene mutations in GI cancers can be targeted by the immune system in individuals with specific HLA gene types. Researchers want to see if they can stop certain GI cancers from returning or spreading.
A clinical trial led by Nicholas D. Klemen, M.D., Physician-Scientist Early Investigator in the Surgery Branch, is researching a therapy using modified T cells, a type of immune cell, for adults with gastrointestinal cancers that have certain gene types and mutations.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov
Clinicaltrials.gov identifier: NCT06690281
NCI Protocol ID: IRB001870
Official Title: A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
